IL18BP and psoriasis: IL-18, which acts as a promoter to interferon (IFN)-γ production, is inactivated by circulating levels of IL-18BP, but a study on psoriasis has shown that, in order to be deactivated, medium doses of IL-18BP need to be administered, while a higher dose does not produce the supposed anti-inflammatory effect [13].